Glatiramer acetate attenuates the activation of CD4 + T cells by modulating STAT1 and â'3 signaling in glia

Ye Hyeon Ahn, Sae Bom Jeon, Chi Young Chang, Eun Ah Goh, Sang Soo Kim, Ho Jin Kim, Jaewhan Song, Eun Jung Park

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Interactions between immune effector cells of the central nervous system appear to directly or indirectly influence the progress/regression of multiple sclerosis (MS). Here, we report that glial STAT1 and a '3 are distinctively phosphorylated following the interaction of activated lymphocytes and glia, and this effect is significantly inhibited by glatiramer acetate (GA), a disease-modifying drug for MS. GA also reduces the activations of STAT1 and a '3 by MS-Associated stimuli such as IFNI 3 or LPS in primary glia, but not neurons. Experiments in IFNI 3-And IFNI 3 receptor-deficient mice revealed that GA-induced inhibitions of STAT signaling are independent of IFNI 3 and its receptor. Interestingly, GA induces the expression levels of suppressor of cytokine signaling-1 and a '3, representative negative regulators of STAT signaling in glia. We further found that GA attenuates the LPS-Triggered enhancement of IL-2, a highly produced cytokine in patients with active MS, in CD4 + T cells co-cultured with glia, but not in CD4 + T cells alone. Collectively, these results provide that activation of glial STATs is an essential event in the interaction between glia and T cells, which is a possible underlying mechanism of GA action in MS. These findings provide an insight for the development of targeted therapies against MS.

Original languageEnglish
Article number40484
JournalScientific reports
Volume7
DOIs
Publication statusPublished - 2017 Jan 17

Fingerprint

Neuroglia
Multiple Sclerosis
T-Lymphocytes
Cytokines
Glatiramer Acetate
Interleukin-2
Central Nervous System
Lymphocytes
Neurons
Pharmaceutical Preparations

All Science Journal Classification (ASJC) codes

  • General

Cite this

Ahn, Y. H., Jeon, S. B., Chang, C. Y., Goh, E. A., Kim, S. S., Kim, H. J., ... Park, E. J. (2017). Glatiramer acetate attenuates the activation of CD4 + T cells by modulating STAT1 and â'3 signaling in glia. Scientific reports, 7, [40484]. https://doi.org/10.1038/srep40484
Ahn, Ye Hyeon ; Jeon, Sae Bom ; Chang, Chi Young ; Goh, Eun Ah ; Kim, Sang Soo ; Kim, Ho Jin ; Song, Jaewhan ; Park, Eun Jung. / Glatiramer acetate attenuates the activation of CD4 + T cells by modulating STAT1 and â'3 signaling in glia. In: Scientific reports. 2017 ; Vol. 7.
@article{1168a35efcf24911a45e26569866c11e,
title = "Glatiramer acetate attenuates the activation of CD4 + T cells by modulating STAT1 and {\^a}'3 signaling in glia",
abstract = "Interactions between immune effector cells of the central nervous system appear to directly or indirectly influence the progress/regression of multiple sclerosis (MS). Here, we report that glial STAT1 and a '3 are distinctively phosphorylated following the interaction of activated lymphocytes and glia, and this effect is significantly inhibited by glatiramer acetate (GA), a disease-modifying drug for MS. GA also reduces the activations of STAT1 and a '3 by MS-Associated stimuli such as IFNI 3 or LPS in primary glia, but not neurons. Experiments in IFNI 3-And IFNI 3 receptor-deficient mice revealed that GA-induced inhibitions of STAT signaling are independent of IFNI 3 and its receptor. Interestingly, GA induces the expression levels of suppressor of cytokine signaling-1 and a '3, representative negative regulators of STAT signaling in glia. We further found that GA attenuates the LPS-Triggered enhancement of IL-2, a highly produced cytokine in patients with active MS, in CD4 + T cells co-cultured with glia, but not in CD4 + T cells alone. Collectively, these results provide that activation of glial STATs is an essential event in the interaction between glia and T cells, which is a possible underlying mechanism of GA action in MS. These findings provide an insight for the development of targeted therapies against MS.",
author = "Ahn, {Ye Hyeon} and Jeon, {Sae Bom} and Chang, {Chi Young} and Goh, {Eun Ah} and Kim, {Sang Soo} and Kim, {Ho Jin} and Jaewhan Song and Park, {Eun Jung}",
year = "2017",
month = "1",
day = "17",
doi = "10.1038/srep40484",
language = "English",
volume = "7",
journal = "Scientific Reports",
issn = "2045-2322",
publisher = "Nature Publishing Group",

}

Glatiramer acetate attenuates the activation of CD4 + T cells by modulating STAT1 and â'3 signaling in glia. / Ahn, Ye Hyeon; Jeon, Sae Bom; Chang, Chi Young; Goh, Eun Ah; Kim, Sang Soo; Kim, Ho Jin; Song, Jaewhan; Park, Eun Jung.

In: Scientific reports, Vol. 7, 40484, 17.01.2017.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Glatiramer acetate attenuates the activation of CD4 + T cells by modulating STAT1 and â'3 signaling in glia

AU - Ahn, Ye Hyeon

AU - Jeon, Sae Bom

AU - Chang, Chi Young

AU - Goh, Eun Ah

AU - Kim, Sang Soo

AU - Kim, Ho Jin

AU - Song, Jaewhan

AU - Park, Eun Jung

PY - 2017/1/17

Y1 - 2017/1/17

N2 - Interactions between immune effector cells of the central nervous system appear to directly or indirectly influence the progress/regression of multiple sclerosis (MS). Here, we report that glial STAT1 and a '3 are distinctively phosphorylated following the interaction of activated lymphocytes and glia, and this effect is significantly inhibited by glatiramer acetate (GA), a disease-modifying drug for MS. GA also reduces the activations of STAT1 and a '3 by MS-Associated stimuli such as IFNI 3 or LPS in primary glia, but not neurons. Experiments in IFNI 3-And IFNI 3 receptor-deficient mice revealed that GA-induced inhibitions of STAT signaling are independent of IFNI 3 and its receptor. Interestingly, GA induces the expression levels of suppressor of cytokine signaling-1 and a '3, representative negative regulators of STAT signaling in glia. We further found that GA attenuates the LPS-Triggered enhancement of IL-2, a highly produced cytokine in patients with active MS, in CD4 + T cells co-cultured with glia, but not in CD4 + T cells alone. Collectively, these results provide that activation of glial STATs is an essential event in the interaction between glia and T cells, which is a possible underlying mechanism of GA action in MS. These findings provide an insight for the development of targeted therapies against MS.

AB - Interactions between immune effector cells of the central nervous system appear to directly or indirectly influence the progress/regression of multiple sclerosis (MS). Here, we report that glial STAT1 and a '3 are distinctively phosphorylated following the interaction of activated lymphocytes and glia, and this effect is significantly inhibited by glatiramer acetate (GA), a disease-modifying drug for MS. GA also reduces the activations of STAT1 and a '3 by MS-Associated stimuli such as IFNI 3 or LPS in primary glia, but not neurons. Experiments in IFNI 3-And IFNI 3 receptor-deficient mice revealed that GA-induced inhibitions of STAT signaling are independent of IFNI 3 and its receptor. Interestingly, GA induces the expression levels of suppressor of cytokine signaling-1 and a '3, representative negative regulators of STAT signaling in glia. We further found that GA attenuates the LPS-Triggered enhancement of IL-2, a highly produced cytokine in patients with active MS, in CD4 + T cells co-cultured with glia, but not in CD4 + T cells alone. Collectively, these results provide that activation of glial STATs is an essential event in the interaction between glia and T cells, which is a possible underlying mechanism of GA action in MS. These findings provide an insight for the development of targeted therapies against MS.

UR - http://www.scopus.com/inward/record.url?scp=85009936518&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85009936518&partnerID=8YFLogxK

U2 - 10.1038/srep40484

DO - 10.1038/srep40484

M3 - Article

VL - 7

JO - Scientific Reports

JF - Scientific Reports

SN - 2045-2322

M1 - 40484

ER -